Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03946358
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : July 27, 2021
Sponsor:
Collaborators:
Roche Pharma AG
National Cancer Institute, France
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Besancon

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : September 2022
Publications: